GB Nagar: Himachal Drug Makers Booked For Sub-Standard Medicines

NOIDA: The drugs control department of Gautam Budh Nagar district has registered a case against two Himachal Pradesh-located manufacturers/producers for allegedly making and selling “unfit” antibiotic medicines, officials aware of the matter informed on Thursday.

A recent inspection conducted across medical stores operating in Gautam Budh Nagar revealed that the two medicines “moxfaith” and “moxaveri” were “sub-standard” or “adulterated”, and unsafe for consumption, they said.

A case has been registered against the erring manufacturers and further legal action is underway, informed officials.

Inspections were conducted following directions of the Food Safety and Drug Administration Department and Gautam Budh Nagar district magistrate Manish Kumar Verma recently to ensure drugs being sold at medical stores and pharmacies are up to required safety standards.

The medicines found unfit during inspections were confiscated by the department, said district drug inspector Vaibhav Babbar.

“Raids were conducted at several pharmacies and medical stores operating in different parts of the district recently. It came to light that two antibiotic medicines that were being manufactured by Himachal Pradesh-based production units were ‘sub-standard’ and ‘unfit’ for consumption,” said Babbar.

According to the information from the district drug control department, the two firms based in Himachal Pradesh have been booked under relevant Sections of the Drugs and Cosmetics Act, 1940.

“Samples of the two medicines were collected and sent for examination which revealed them to be of ‘substandard’ quality,” Babbar said.

“Manufacturing and selling drugs ‘unfit’ for consumption is a violation of Section 18 (prohibition of manufacture and sale of certain drugs and cosmetics) and is a punishable offence under Section 27 of the Drugs and Cosmetics Act, 1940”, added the district drug inspector, he added.

Earlier this year, the regional ayurvedic and unani office, Gautam Budh Nagar, had banned the production, supply and sale of several ayurveda pills and powders after being allegedly found to be “spurious” and “adulterated”, having composition of allopathic drugs including Prednisolone, Diclofenac, Betamethasone, among others.

Related Posts

India’s Pharma Sector Must Expand AI Use Beyond R&D: Reports

The report emphasizes that absolute R&D spending remains modest and identifies expanding investment in advanced biologics and AI-driven drug discovery as the “largest opportunity” for bridging the innovation divide. Recent…

India’s Pharma, Healthcare Funding Hits $38.6 Mn in Nov’25

Early-stage activity drove the month, accounting for 73.6 per cent of total investments, while seed-stage rounds contributed the remaining 26.4 per cent. India’s pharma and healthcare funding for November 2025…

Leave a Reply

Your email address will not be published. Required fields are marked *

You Missed

India’s Pharma Sector Must Expand AI Use Beyond R&D: Reports

India’s Pharma Sector Must Expand AI Use Beyond R&D: Reports

India headed for Culture of ‘Divya Buildings’, thanks to AMTZ’s Landmark Initiative

India headed for Culture of ‘Divya Buildings’, thanks to AMTZ’s Landmark Initiative

India’s Pharma, Healthcare Funding Hits $38.6 Mn in Nov’25

India’s Pharma, Healthcare Funding Hits $38.6 Mn in Nov’25

Novo Nordisk gears up for December Ozempic launch

Novo Nordisk gears up for December Ozempic launch

Illegal intoxicant tablets seized in large quantity from Sirsa medical store, two held

Illegal intoxicant tablets seized in large quantity from Sirsa medical store, two held

Higher pharma, chemicals exports to Russia bloc on agenda to trim deficit

Higher pharma, chemicals exports to Russia bloc on agenda to trim deficit